KCT0008254
Not Yet Recruiting
N/A
Comprehensive study for the potential blood-based biomarkers for EGFR-mutant NSCLC patients treated with lazertinib
Kyung Hee University Hospital0 sites100 target enrollmentTBD
ConditionsNeoplasms
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Neoplasms
- Sponsor
- Kyung Hee University Hospital
- Enrollment
- 100
- Status
- Not Yet Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) A person who has given written consent to participate in this study
- •2\) Adult men and women over 19 years of age
- •3\) Patients with histologically or cytologically confirmed non\-small cell lung cancer
- •4\) Patients scheduled to receive Lazertinib after T790M mutation was confirmed positive after treatment failure with 1st or 2nd generation EGFR\-TKIs
- •5\) Patients with ECOG PS of 0\~2
Exclusion Criteria
- •1\) Patients who have received systemic steroid or immunosuppressant treatment within 2 weeks prior to Lazertinib administration
- •2\) Patients who received antibiotic treatment within 2 weeks prior to Lazertinib administration
- •3\) Patients currently being treated for connective tissue disease or inflammatory bowel disease
- •4\) Patients confirmed as positive for ALK fusion
- •5\) Patients with confirmed malignant tumors prior to participating in this study
- •However, registration is possible in the following cases, but registration is not possible if the patient is accompanied by a malignant tumor requiring current treatment.
- •\- Cases confirmed as malignant tumors (including lung cancer) but in remission for more than 5 years after completion of treatment
- •\-Efficiently treated non\-melanoma skin cancer, cervical carcinoma in situ, mammary ductal carcinoma in situ, localized prostate cancer, and thyroid cancer treated for curative purposes can be registered.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Investigating the effect of using the blood of a brain dead liver donor patient during liver transplantation on the liver recipient patientIVER TRANSPLANT.Surgical operation with transplant of whole organ as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedureY83.0IRCT20211008052699N2Shiraz University of Medical Sciences124
Recruiting
N/A
Tissue and Blood-based Biomarker in Colorectal CancerACTRN12621000976886The Walter and Eliza Hall Institute of Medical Research (WEHI)1,000
Completed
N/A
Prospective study to examine whether Blood N-terminal proBNP (N-terminal pro brain natriuretic peptide) can be used as an indicator of cardiac preload during massive fluid resuscitation in critically ill patients.JPRN-UMIN000004671Emergency Medicine60
Completed
N/A
A study to evaluate the response of whole blood stimulation with lipopolysaccharide or other inducers and its in vitro inhibition in healthy volunteers, and patients with a chronic inflammatory conditioatheroscleroserheumatoid arthritis100110821000381610003216NL-OMON38316Centre for Human Drug Research250
Recruiting
N/A
Analysis of genome and blood components for elucidation and treatment on mood disorderMood disorderJPRN-UMIN000006264Social medical corporation Koutokukai Sato Hospital10,000